REVOLUTION MEDICINES, INC.
RVMD evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Market Cap:
- $43.96B
- Lead Asset:
- daraxonrasib (Phase 3)
What it means
What to watch
Prepared research question
What matters most for RVMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RVMD
Revolution Medicines (RVMD) is a commercial-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers, with an FDA-approved product (RASONQUE/daraxonrasib) for metastatic pancreatic cancer and a pipeline of combination therapies in Phase 3 trials.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 18 clinical trials · 1 FDA decision for REVOLUTION MEDICINES, INC..
Revolution Medicines (RVMD) is a commercial-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers, with an FDA-approved product (RASONQUE/daraxonrasib) for metastatic pancreatic cancer and a pipeline of combination therapies in Phase 3 trials.
- Revolution Medicines is a commercial-stage oncology company focused on RAS-addicted cancers [news · 2026-10-05].
- As of 2026-06-30, the company reported cash & equivalents of $815.4M, net income of -$644.4M, and shareholders' equity of $2,606.2M [sec].
- RASONQUE (daraxonrasib) received FDA approval for metastatic pancreatic cancer in August 2026 [news · 2026-08-28].
- The company is advancing zoldonrasib in Phase 3 trials and has initiated the RASolute 309 global Phase 3 trial for a combination of RASONQUE and zoldonrasib as first-line treatment [news · 2026-10-05].
- FDA granted Breakthrough Therapy Designation to RASONQUE plus chemotherapy for treatment-naïve metastatic pancreatic adenocarcinoma in September 2026 [news · 2026-09-23].
What works
- FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic cancer provides a commercial-stage revenue stream and validates the RAS-targeted approach [news · 2026-08-28].
- Breakthrough Therapy Designation for RASONQUE plus chemotherapy in first-line PDAC may accelerate development and regulatory interactions [news · 2026-09-23].
- Cash & equivalents of $815.4M as of 2026-06-30 provide a substantial runway to fund ongoing clinical programs and commercial launch [sec].
- Multiple Phase 3 trials (RASolute 302, 303, 304, 305, RASolve 301) and a new global Phase 3 trial (RASolute 309) demonstrate a deep late-stage pipeline [sec_mda · as of 2026-02-25].
What to weigh
- The company reported a net loss of -$644.4M for the period ending 2026-06-30, reflecting high R&D and commercialization costs [sec].
- Clinical-stage oncology development carries inherent risks of trial delays, regulatory hurdles, or negative outcomes that could materially harm the business [sec_mda · as of 2026-02-25].
- The company's cash position decreased from $2.0B as of 2025-12-31 to $815.4M as of 2026-06-30, indicating significant cash burn [sec_mda · as of 2026-02-25].
- Dependence on successful development of current and future product candidates, with many programs still in preclinical or early clinical stages [sec_mda · as of 2026-02-25].
From the filings
Quoted directly from source documents.
Company description and focus
“We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers.”
SEC MD&A · February 25, 2026
FDA approval of RASONQUE
“Revolution Medicines, Inc. (NASDAQ:RVMD) touched an all-time high above $224 on August 27, 2026, following FDA approval of Rasonque (daraxonrasib) – the first broad RAS-targeted therapy cleared for metastatic pancreatic cancer.”
News · August 28, 2026
Breakthrough Therapy Designation
“the FDA granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib) plus chemotherapy for treatment‑naïve metastatic pancreatic adenocarcinoma”
News · September 23, 2026
Cash position as of 2025-12-31
“As of December 31, 2025, we had cash, cash equivalents and marketable securities of $2.0 billion.”
SEC MD&A · February 25, 2026
Catalyst timeline
- 2021-04-07 · Phase 1 start for RMC 5552 monotherapy — A Phase 1/1b dose-escalation study of RMC 5552 monotherapy in relapsed/refractory solid tumors.
- 2021-12-30 · Phase 2 start for RMC-4630 plus sotorasib — A Phase 2 study of RMC-4630 combined with sotorasib for KRASG12C mutant NSCLC.
- 2022-05-31 · Phase 2 start for RMC-6236 — A multicenter open-label study of RMC-6236 in advanced solid tumors with specific RAS mutations.
- 2022-09-19 · Phase 1 start for RMC-6291 monotherapy — A Phase 1/1b dose escalation and expansion study of RMC-6291 in KRASG12C mutant solid tumors.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — If clinical trials fail or are delayed, the business will be materially harmed [sec_mda · as of 2026-02-25].
- Cash burn rate — Cash decreased from $2.0B (2025-12-31) to $815.4M (2026-06-30), indicating high spending [sec_mda · as of 2026-02-25].
- Dependence on pipeline — Business success depends on successful development of current and future product candidates, many preclinical [sec_mda · as of 2026-02-25].
- Commercial execution risk — Expanding global launch strategy increases difficulty of achievement [sec · filed 2026-04-27].
What to watch
- Progress of the RASolute 309 Phase 3 trial for RASONQUE plus zoldonrasib as first-line treatment, initiated in October 2026 [news · 2026-10-05].
- Commercial uptake and revenue from RASONQUE following FDA approval in August 2026 [news · 2026-08-28].
- Outcome of Breakthrough Therapy Designation for RASONQUE plus chemotherapy in first-line PDAC [news · 2026-09-23].
- Cash runway and burn rate, given the decrease from $2.0B to $815.4M over six months [sec_mda · as of 2026-02-25].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run REVOLUTION MEDICINES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available REVOLUTION MEDICINES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.66 · 0% dilution
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
0 buys · 57 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
511
Total value held
$18.59B
| Holder | Shares | Value |
|---|---|---|
| farallon capital management llc | 13,604,796 | $1.32B |
| blackrock, inc. | 11,212,706 | $1.09B |
| janus henderson group plc | 9,766,496 | $949.5M |
| baker bros. advisors lp | 9,555,357 | $929.3M |
| fmr llc | 8,464,314 | $823.2M |
| vanguard capital management llc | 8,362,284 | $813.2M |
| nextech invest, ltd. | 7,601,087 | $739.2M |
| vanguard portfolio management llc | 7,502,623 | $729.6M |
| paradigm biocapital advisors lp | 6,655,703 | $647.3M |
| wellington management group llp | 6,027,819 | $586.2M |
Showing top 10 of 511 institutional holders of REVOLUTION MEDICINES, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 24, 2026- % of float
- 8.2%
- Days to cover
- 8.0
- Shares short
- 15,409,530
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RVMD short interestGovernance
Frequently asked questions
What is the AI investment thesis for REVOLUTION MEDICINES, INC.?
Revolution Medicines (RVMD) is a commercial-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers, with an FDA-approved product (RASONQUE/daraxonrasib) for metastatic pancreatic cancer and a pipeline of combination therapies in Phase 3 trials.
What is REVOLUTION MEDICINES, INC.'s lead drug candidate?
REVOLUTION MEDICINES, INC.'s most advanced tracked candidate is daraxonrasib (Phase 3) for Non-small Cell Lung Cancer (NSCLC); PDAC; Pancreatic Cancer.
Who is the CEO of REVOLUTION MEDICINES, INC.?
Dr. Mark A. Goldsmith M.D., Ph.D. is the chief executive officer of REVOLUTION MEDICINES, INC. (RVMD).
Where is REVOLUTION MEDICINES, INC. headquartered?
REVOLUTION MEDICINES, INC. (RVMD) is headquartered in Redwood City, CA, United States.
What therapeutic areas does REVOLUTION MEDICINES, INC. focus on?
REVOLUTION MEDICINES, INC. develops therapies across Oncology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.